Key result
Continuation of renin-angiotensin-aldosterone system blockade less than three months after hospitalization for acute kidney injury was associated with lower mortality in veterans.
Why the study?
Does the discontinuation of RAASB improve renal recovery without increasing mortality in patients with AKI or advanced CKD?
Does the discontinuation of RAASB improve renal recovery without increasing mortality in patients with AKI or advanced CKD?
Answers are grounded in this paper and cite their sources.
The editorial emphasizes that a trial withdrawal of RAASB is a reasonable option for unexplained progressive AKI, but underscores the urgent need for a randomized controlled trial to resolve conflicting observational data.
Unquestionably, there is a common consensus regarding cardiorenal protection with renin-angiotensin-aldosterone system blockade (RAASB) in both diabetic and nondiabetic chronic kidney disease (CKD). Nevertheless, there remain conflicting retrospective reports regarding renal and cardiovascular mortality outcomes following discontinuation of RAASB in advanced CKD. We present an editorial on a recent article discussing renal and mortality outcomes among hospitalized veterans who were started back on RAASB versus those who were not started back on RAASB. The controversy surrounding this topic thickens as the analysis unfolds.
No takes yet. Share an insight, caveat, or question.
Macaulay A C Onuigbo (2023) conducted an editorial in Acute Kidney Injury (n=54,735). Renin-angiotensin-aldosterone system blockade (RAASB) vs. Non-continuation of RAASB was evaluated on Mortality. Continuation of renin-angiotensin-aldosterone system blockade less than three months after hospitalization for acute kidney injury was associated with lower mortality in veterans.
Synapse has enriched 10 related papers. Consider them for comparative context: